These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24032262)

  • 1. [The value of Ki-67 antigen expression in tissue microarray method in prediction prognosis of patients with endometrioid endometrial cancer].
    Gottwald L; Kubiak R; Sek P; Piekarski J; Szwalski J; Pasz-Walczak G; Spych M; Suzin J; Tylińskis W; Jeziorski A
    Ginekol Pol; 2013 Jun; 84(6):444-9. PubMed ID: 24032262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer].
    Gottwald L; Kubiak R; Pasz-Walczak G; Sek P; Piekarski J; Szwalski J; Spych M; Chałubińska-Fendler J; Suzin J; Tyliński W; Jeziorski A
    Ginekol Pol; 2013 Feb; 84(2):95-101. PubMed ID: 23668054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of tissue microarray technique for the assessment of estrogen and progesterone receptors expression in endometrioid endometrial cancer--preliminary report].
    Gottwald L; Sek P; Kubiak R; Pasz-Walczak G; Piekarski J; Szwalski J; Suzin J; Tyliński W; Hendzel K; Jeziorski A
    Ginekol Pol; 2012 May; 83(5):342-6. PubMed ID: 22708330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of ki-67 in breast carcinoma: tissue microarray method versus whole section analysis- potentials and pitfalls.
    Dedić Plavetić N; Jakić-Razumović J; Kulić A; Sirotković-Skerlev M; Barić M; Vrbanec D
    Pathol Oncol Res; 2015 Apr; 21(2):315-24. PubMed ID: 25096394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endometrioid endometrial cancer--the prognostic value of selected clinical and pathological parameters].
    Gottwald L; Chałubińska J; Moszyńska-Zielińska M; Piekarski J; Tyliński W; Szwalski J; Kubiak R; Pasz-Walczak G; Hendzel K; Ciałkowska-Rysz A
    Ginekol Pol; 2011 Oct; 82(10):743-8. PubMed ID: 22379937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
    Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ
    Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cleaved caspase-3 expression is a potential prognostic factor for endometrial cancer with positive peritoneal cytology.
    Ogane N; Yasuda M; Kato H; Kato T; Yano M; Kameda Y; Kamoshida S
    Cytopathology; 2018 Jun; 29(3):254-261. PubMed ID: 29626374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of a tissue microarray with two millimeters cores of endometrioid endometrial cancer: factors affecting the quality of the recipient block.
    Gottwald L; Sęk P; Piekarski J; Pasz-Walczak G; Kubiak R; Szwalski J; Spych M; Suzin J; Tyliński W; Topczewska-Tylinska K; Jeziorski A
    Biotech Histochem; 2012 Nov; 87(8):512-8. PubMed ID: 22909182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
    Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
    Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
    Han KH; Kim HS; Lee M; Chung HH; Song YS
    Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.
    Huvila J; Laajala TD; Edqvist PH; Mardinoglu A; Talve L; Pontén F; Grénman S; Carpén O; Aittokallio T; Auranen A
    Gynecol Oncol; 2018 Apr; 149(1):173-180. PubMed ID: 29486992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
    Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
    Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
    Bildrici K; Tel N; Ozalp SS; Yalcin OT; Yilmaz V
    Eur J Gynaecol Oncol; 2002; 23(6):540-4. PubMed ID: 12556100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MELF Pattern for Predicting Lymph Node Involvement and Survival in Grade I-II Endometrioid-type Endometrial Cancer.
    Sanci M; Güngördük K; Gülseren V; Karadeniz T; Kocaer M; Gungorduk O; Özdemir İA
    Int J Gynecol Pathol; 2018 Jan; 37(1):17-21. PubMed ID: 28319574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Wnt7a is associated with tumor progression and unfavorable prognosis in endometrial cancer.
    Liu Y; Meng F; Xu Y; Yang S; Xiao M; Chen X; Lou G
    Int J Gynecol Cancer; 2013 Feb; 23(2):304-11. PubMed ID: 23321718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.
    Yang JY; Werner HM; Li J; Westin SN; Lu Y; Halle MK; Trovik J; Salvesen HB; Mills GB; Liang H
    Clin Cancer Res; 2016 Jan; 22(2):513-23. PubMed ID: 26224872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of prognosis in patients with endometrioid endometrial cancer staged IB in FIGO 1988 and 2009 classifications.
    Gottwald L; Moszynska-Zielińska M; Spych M; Korczynski J; Tylinski W; Szwalski J; Kubiak R; Pasz-Walczak G; Sobotkowski J; Suzin J; Piekarski J
    Arch Gynecol Obstet; 2012 Oct; 286(4):995-1000. PubMed ID: 22627994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.